Ask AI
ProCE Banner Activity

TROPION-Lung02: Phase I Study of First-line Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC

Conference Coverage
Slideset

Results from the final analysis from TROPION-Lung02 evaluating first-line Dato-DXd plus pembrolizumab with or without platinum chemotherapy in patients with advanced NSCLC suggest encouraging efficacy and safety in support of ongoing clinical development.

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar